SCHEMBL17061758

SCHEMBL17061758

CC(C)(C)OC(=O)c1cc(C2CC2)c(COS(C)(=O)=O)cc1F

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 19/20 0.48
▸ SCN5A Q14524 2/20 0.38
▸ SCN7A Q01118 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19411407 0.84 SCN9A (0.52) SCN9ASCN5ASCN7A
SCHEMBL21075309 0.84 SCN9A (0.44) SCN9ASCN5ASCN7AGPR119
SCHEMBL15599202 0.83 SCN9A (0.43) SCN9ASCN5ASCN7AGPR119
SCHEMBL16759482 0.82 SCN9A (0.42) SCN9ASCN5ASCN7A
SCHEMBL16771098 0.82 SCN9A (0.42) SCN9ASCN5ASCN7AGPR119
SCHEMBL16758984 0.79 SCN9A (0.40) SCN9ASCN5ASCN7AGPR119
SCHEMBL15599293 0.79 SCN9A (0.71) SCN9ASCN5ASCN7A
SCHEMBL17062393 0.79 SCN9A (0.49) SCN9ASCN5ASCN7AGPR119
SCHEMBL16771146 0.79 SCN9A (0.49) SCN9ASCN5ASCN7AGPR119
SCHEMBL17062394 0.79 SCN9A (0.49) SCN9ASCN5ASCN7AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11203572-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2021-12-21 — — US disclosed
EP-3854782-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2021-07-28 — — EP disclosed
US-20210155588-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-05-27 — — US disclosed
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 — — US disclosed
EP-3436432-B1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-01-27 — — EP disclosed
US-10766858-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2020-09-08 — — US disclosed
US-20200108054-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2020-04-09 — — US disclosed
CN-105793238-B Substituted benzamides and methods of use thereof 基因泰克公司 2019-12-24 — — CN disclosed
US-20190112264-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-04-18 — — US disclosed
US-9694002-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-07-04 — — US disclosed
US-20170087136-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-03-30 — — US disclosed
US-9546164-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-01-17 — — US disclosed
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2015-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155588-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, RRM1 SCN9A 1549/4885SCN5A 649/4885SCN7A 1288/4885
US-11203572-B2 Substituted benzamides and methods of use thereof BRIX1, RDX, RRM1 SCN9A 1549/4885SCN5A 649/4885SCN7A 1288/4885
US-20190112264-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 SCN9A 1547/4885SCN5A 752/4885SCN7A 1331/4885
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 SCN9A 1605/4885SCN5A 628/4885SCN7A 1270/4885
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, RRM1 SCN9A 1669/4885SCN5A 640/4885SCN7A 1496/4885
US-10766858-B2 Substituted benzamides and methods of use thereof BRIX1, RDX, SULT2A1 SCN9A 1547/4885SCN5A 752/4885SCN7A 1331/4885
US-20170087136-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF C1R, SRR, PNISR SCN9A 505/4885SCN5A 631/4885SCN7A 258/4885
US-20200108054-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 SCN9A 1605/4885SCN5A 628/4885SCN7A 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback